Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update

References

• Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep.125(Suppl. 3), 16–26 (2010).
   PubMed Web of Science ®Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine26(Suppl. 4), D49–D53 (2008).
   PubMed Web of Science ®Google Scholar
• Dugan VG, Chen R, Spiro DJ et al. The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS Pathog.4(5), e1000076 (2008).
   PubMed Web of Science ®Google Scholar
• Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev.56(1), 152–179 (1992).
   PubMedGoogle Scholar
• Alexander DJ. Avian influenza viruses and human health. Dev. Biol. (Basel)124, 77–84 (2006).
   PubMedGoogle Scholar
• Kalthoff D, Globig A, Beer M. (Highly pathogenic) avian influenza as a zoonotic agent. Vet. Microbiol.140(3–4), 237–245 (2010).
   PubMed Web of Science ®Google Scholar
• Malik Peiris JS. Avian influenza viruses in humans. Rev. Sci. Tech.28(1), 161–173 (2009).
   PubMed Web of Science ®Google Scholar
• Huang AS, Palma EL, Hewlett N, Roizman B. Pseudotype formation between enveloped RNA and DNA viruses. Nature252(5485), 743–745 (1974).
   PubMedGoogle Scholar
• Rubin H. Genetic control of cellular susceptibility to pseudotypes of rous sarcoma virus. Virology26, 270–276 (1965).
   PubMed Web of Science ®Google Scholar
• Zavada J, Rosenbergova M. Phenotypic mixing of vesicular stomatitis virus with fowl plague virus. Acta. Virol.16(2), 103–114 (1972).
   PubMed Web of Science ®Google Scholar
• Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr. Gene Ther.8(6), 449–460 (2008).
   PubMed Web of Science ®Google Scholar
• Verhoeyen E, Cosset FL. Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer. Cold Spring Harb. Protoc. DOI:10.1101/pdb.top59 (2009) (Epub ahead of print).
   Google Scholar
• Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE3(1), e1501 (2008).
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE4(6), e6032 (2009).
   PubMed Web of Science ®Google Scholar
• Wu Q, Fang L, Wu X et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol.46(11–12), 2210–2217 (2009).
   PubMed Web of Science ®Google Scholar
• Dong J, Roth MG, Hunter E. A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J. Virol.66(12), 7374–7382 (1992).
   PubMedGoogle Scholar
• Baum C, Schambach A, Bohne J, Galla M. Retrovirus vectors: toward the plentivirus? Mol. Ther.13(6), 1050–1063 (2006).
   PubMed Web of Science ®Google Scholar
• McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther.13(8), 715–724 (2006).
   PubMed Web of Science ®Google Scholar
• Oh S, Selleck P, Temperton NJ et al. Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses. J. Virol. Methods157(2), 161–167 (2009).
   PubMedGoogle Scholar
• Su CY, Wang SY, Shie JJ et al. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Res.79(3), 199–205 (2008).
   PubMedGoogle Scholar
• Szecsi J, Boson B, Johnsson P et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J.3, 70 (2006).
   PubMed Web of Science ®Google Scholar
• Wang SY, Su CY, Lin M et al. HA-pseudotyped retroviral vectors for influenza antagonist screening. J. Biomol. Screen.14(3), 294–302 (2009).
   PubMedGoogle Scholar
• Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol.86(Pt 5), 1455–1465 (2005).
   PubMedGoogle Scholar
• Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol.75(3), 1576–1580 (2001).
   PubMed Web of Science ®Google Scholar
• Matsuno K, Kishida N, Usami K et al. Different potential of C-type lectin-mediated entry between Marburg virus strains. J. Virol.84(10), 5140–5147 (2010).
   PubMedGoogle Scholar
• Roth MG, Compans RW. Delayed appearance of pseudotypes between vesicular stomatitis virus influenza virus during mixed infection of MDCK cells. J. Virol.40(3), 848–860 (1981).
   PubMedGoogle Scholar
• Bupp K, Gonzalez-Scarano F. Pseudotype formation with La Crosse virus glycoproteins. J. Gen. Virol.79(Pt 4), 667–671 (1998).
   PubMedGoogle Scholar
• Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol.83(10), 5192–5203 (2009).
   PubMed Web of Science ®Google Scholar
• Briggs JA, Wilk T, Fuller SD. Do lipid rafts mediate virus assembly and pseudotyping? J. Gen. Virol.84(Pt 4), 757–768 (2003).
   PubMed Web of Science ®Google Scholar
• Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseudotyping. J. Virol.75(15), 7175–7183 (2001).
   PubMedGoogle Scholar
• Sandrin V, Cosset FL. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J. Biol. Chem.281(1), 528–542 (2006).
   PubMedGoogle Scholar
• Ali A, Avalos RT, Ponimaskin E, Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol.74(18), 8709–8719 (2000).
   PubMed Web of Science ®Google Scholar
• Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol.82(20), 10059–10070 (2008).
   PubMed Web of Science ®Google Scholar
• Nayak DP, Balogun RA, Yamada H, Zhou ZH, Barman S. Influenza virus morphogenesis and budding. Virus Res.143(2), 147–161 (2009).
   PubMed Web of Science ®Google Scholar
• Radyukhin V, Fedorova N, Ksenofontov A, Serebryakova M, Baratova L. Cold co-extraction of hemagglutinin and matrix M1 protein from influenza virus A by a combination of non-ionic detergents allows for visualization of the raft-like nature of the virus envelope. Arch. Virol.153(10), 1977–1980 (2008).
   PubMedGoogle Scholar
• Hammarstedt M, Garoff H. Passive and active inclusion of host proteins in human immunodeficiency virus type 1 gag particles during budding at the plasma membrane. J. Virol.78(11), 5686–5697 (2004).
   PubMed Web of Science ®Google Scholar
• Kueng HJ, Schmetterer KG, Pickl WF. Lipid rafts, pseudotyping, and virus-like particles: relevance of a novel, configurable, and modular antigen-presenting platform. Int. Arch. Allergy Immunol.154(2), 89–110 (2010).
   PubMedGoogle Scholar
• Leung K, Kim JO, Ganesh L, Kabat J, Schwartz O, Nabel GJ. HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions. Cell Host Microbe3(5), 285–292 (2008).
   PubMed Web of Science ®Google Scholar
• Yue L, Shang L, Hunter E. Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity. J. Virol.83(22), 11588–11598 (2009).
   PubMedGoogle Scholar
• Bischof D, Cornetta K. Flexibility in cell targeting by pseudotyping lentiviral vectors. Methods Mol. Biol.614, 53–68 (2010).
   PubMedGoogle Scholar
• Kim SH, Jang SI, Park CY, You JC. Investigation of requirements for efficient gene delivery using the HIV-1 based lentiviral transduction system. Biochem. Biophys. Res. Commun.383(2), 192–197 (2009).
   PubMedGoogle Scholar
• Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J.11(8), 3053–3058 (1992).
   PubMed Web of Science ®Google Scholar
• Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol.68(1), 510–516 (1994).
   PubMed Web of Science ®Google Scholar
• Hatziioannou T, Valsesia-Wittmann S, Russell SJ, Cosset FL. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J. Virol.72(6), 5313–5317 (1998).
   PubMedGoogle Scholar
• Temperton NJ, Hoschler K, Major D et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses1(3), 105–112 (2007).
   PubMed Web of Science ®Google Scholar
• Barde I, Salmon P, Trono D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. Chapter 4, Unit 4 21 (2010).
   PubMedGoogle Scholar
• Temperton N, Wright E. Retroviral pseudotypes. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd., Chichester, UK. DOI: 10.1002/9780470015902.a0021549 (2009).
   Google Scholar
• Baker M. Biochemistry. Hidden code in the protein code. Nat. Methods7(11), 874 (2010).
   PubMedGoogle Scholar
• Ohuchi M, Cramer A, Vey M, Ohuchi R, Garten W, Klenk HD. Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J. Virol.68(2), 920–926 (1994).
   PubMedGoogle Scholar
• Corti D, Suguitan AL Jr, Pinna D et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest.120(5), 1663–1673 (2010).
   PubMed Web of Science ®Google Scholar
• Lin AH, Cannon PM. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res.83(1–2), 43–56 (2002).
   PubMedGoogle Scholar
• Szecsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset FL. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J. Infect. Dis.200(2), 181–190 (2009).
   PubMed Web of Science ®Google Scholar
• Bosch V, Kramer B, Pfeiffer T, Starck L, Steinhauer DA. Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors. J. Gen. Virol.82(Pt 10), 2485–2494 (2001).
   PubMedGoogle Scholar
• Ao Z, Patel A, Tran K et al. Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res.79(1), 12–18 (2008).
   PubMedGoogle Scholar
• Wang W, Castelan-Vega JA, Jimenez-Alberto A, Vassell R, Ye Z, Weiss CD. A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology407(2), 374–380 (2010).
   PubMedGoogle Scholar
• Thorne N, Inglese J, Auld DS. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol.17(6), 646–657 (2010).
   PubMedGoogle Scholar
• Olesen CE, Yan YX, Liu B et al. Novel methods for chemiluminescent detection of reporter enzymes. Methods Enzymol.326, 175–202 (2000).
   PubMedGoogle Scholar
• Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene Ther.14(14), 1287–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Tom R, Bisson L, Durocher Y. Transfection of HEK293-EBNA1 cells in suspension with linear PEI for production of recombinant proteins. Cold Spring Harb. Protoc. DOI:10.1101/pdb.prot4977 (2008).
   Google Scholar
• Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res.24(4), 596–601 (1996).
   PubMed Web of Science ®Google Scholar
• Salmon P, Trono D. Production and titration of lentiviral vectors. Curr. Protoc. Hum. Genet.12(12), 10 (2007).
   PubMedGoogle Scholar
• Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol.20(5), 298–310 (2010).
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem.69, 531–569 (2000).
   PubMed Web of Science ®Google Scholar
• Bottcher-Friebertshauser E, Freuer C, Sielaff F et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol.84(11), 5605–5614 (2010).
   PubMed Web of Science ®Google Scholar
• Wang W, Butler EN, Veguilla V et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods153(2), 111–119 (2008).
   PubMed Web of Science ®Google Scholar
• Bottcher E, Freuer C, Steinmetzer T, Klenk HD, Garten W. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine27(45), 6324–6329 (2009).
   PubMed Web of Science ®Google Scholar
• Kutner RH, Puthli S, Marino MP, Reiser J. Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol.9, 10 (2009).
   PubMed Web of Science ®Google Scholar
• Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc.4(4), 495–505 (2009).
   PubMed Web of Science ®Google Scholar
• Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum. Gene Ther.6(9), 1195–1202 (1995).
   PubMed Web of Science ®Google Scholar
• Ellis BL, Potts PR, Porteus M. Creating higher titer lentivirus using caffeine. Hum. Gene Ther.22(1), 93–100 (2010).
   PubMedGoogle Scholar
• Godbey WT, Wu KK, Hirasaki GJ, Mikos AG. Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther.6(8), 1380–1388 (1999).
   PubMed Web of Science ®Google Scholar
• Ulasov AV, Khramtsov YV, Trusov GA, Rosenkranz AA, Sverdlov ED, Sobolev AS. Properties of PEI-based polyplex nanoparticles that correlate with their transfection efficacy. Mol. Ther.1, 103–112 (2010).
   Google Scholar
• Yue Y, Jin F, Deng R et al. Revisit complexation between DNA and polyethylenimine – effect of uncomplexed chains free in the solution mixture on gene transfection. J. Control. Release DOI:10.1016/j.jconrel.2010.10.028 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Ren Y, Jiang X, Pan D, Mao HQ. Charge density and molecular weight of polyphosphoramidate gene carrier are key parameters influencing its DNA compaction ability and transfection efficiency. Biomacromolecules11(12), 3432–3439 (2010).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine25(35), 6447–6457 (2007).
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, Dai K et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med.2(24), 24ra21 (2010).
   PubMedGoogle Scholar
• Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R. Comparison of lentiviral vector titration methods. BMC Biotechnol.6, 34 (2006).
   PubMed Web of Science ®Google Scholar
• Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther.9(17), 1155–1162 (2002).
   PubMed Web of Science ®Google Scholar
• Transfiguracion J, Coelho H, Kamen A. High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.813(1–2), 167–173 (2004).
   PubMedGoogle Scholar
• Nefkens I, Garcia JM, Ling CS et al. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol.39(1), 27–33 (2007).
   PubMed Web of Science ®Google Scholar
• Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods165(2), 305–310 (2010).
   PubMedGoogle Scholar
• Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz.)58(2), 107–119 (2010).
   PubMed Web of Science ®Google Scholar
• Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol. Ther.18(3), 477–490 (2010).
   PubMed Web of Science ®Google Scholar
• Duisit G, Conrath H, Saleun S et al. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther.6(4), 446–454 (2002).
   PubMedGoogle Scholar
• Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J. Med. Chem.53(20), 7377–7391 (2010).
   PubMed Web of Science ®Google Scholar
• Song G, Yang S, Zhang W et al. Discovery of the first series of small molecule H5N1 entry inhibitors. J. Med. Chem.52(23), 7368–7371 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ito T, Suzuki T et al. Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol.74(24), 11825–11831 (2000).
   PubMed Web of Science ®Google Scholar
• Viswanathan K, Chandrasekaran A, Srinivasan A, Raman R, Sasisekharan V, Sasisekharan R. Glycans as receptors for influenza pathogenesis. Glycoconj. J.27(6), 561–570 (2010).
   PubMedGoogle Scholar
• Zhang H. Tissue and host tropism of influenza viruses: importance of quantitative analysis. Sci. China C Life Sci.52(12), 1101–1110 (2009).
   PubMedGoogle Scholar
• Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull.28(3), 399–408 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. Evolving complexities of influenza virus and its receptors. Trends Microbiol.16(4), 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• Joo KI, Wang P. Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther.15(20), 1384–1396 (2008).
   PubMedGoogle Scholar
• Muthumani K, Montaner LJ, Ayyavoo V, Weiner DB. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1Vpr function in macrophages and T-cells. DNA Cell. Biol.19(3), 179–188 (2000).
   PubMedGoogle Scholar
• Haselhorst T, Garcia JM, Islam T et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew. Chem. Int. Ed. Engl.47(10), 1910–1912 (2008).
   PubMed Web of Science ®Google Scholar
• Su Y, Zhu X, Wang Y, Wu M, Tien P. Evaluation of Glu11 and Gly8 of the H5N1 influenza hemagglutinin fusion peptide in membrane fusion using pseudotype virus and reverse genetics. Arch. Virol.153(2), 247–257 (2008).
   PubMedGoogle Scholar
• Huang IC, Li W, Sui J, Marasco W, Choe H, Farzan M. Influenza A virus neuraminidase limits viral superinfection. J. Virol.82(10), 4834–4843 (2008).
   PubMedGoogle Scholar
• Su B, Wurtzer S, Rameix-Welti MA et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell–cell fusion and virus entry by the viral neuraminidase (NA). PLoS ONE4(12), e8495 (2009).
   PubMedGoogle Scholar
• Joo KI, Tai A, Lee CL, Wong C, Wang P. Imaging multiple intermediates of single-virus membrane fusion mediated by distinct fusion proteins. Microsc. Res. Tech.73(9), 886–900 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin X, Wang G et al. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS ONE5(2), e9167 (2010).
   PubMedGoogle Scholar
• Zhang Y, Lin X, Zhang F et al. Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem. Biophys. Res. Commun.387(2), 405–408 (2009).
   PubMedGoogle Scholar
• Du N, Zhou J, Lin X et al. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J. Virol.84(15), 7822–7831 (2010).
   PubMedGoogle Scholar
• Ho JW, Hershkovitz O, Peiris M et al. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J. Virol.82(4), 2028–2032 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang S, Xiao L, Zhou H et al. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus. J. Virol. Methods154(1–2), 99–103 (2008).
   PubMedGoogle Scholar
• Haynes JR, Dokken L, Wiley JA et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine27(4), 530–541 (2009).
   PubMed Web of Science ®Google Scholar
• Haynes JR. Influenza virus-like particle vaccines. Expert Rev. Vaccines8(4), 435–445 (2009).
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Zhang X et al. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem. Biophys. Res. Commun.397(3), 580–585 (2010).
   PubMedGoogle Scholar
• Alberini I, Del Tordello E, Fasolo A et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine27(43), 5998–6003 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia JM, Pepin S, Lagarde N et al. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS ONE4(11), e7918 (2009).
   PubMed Web of Science ®Google Scholar
• Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS ONE5(6), e11036 (2010).
   PubMed Web of Science ®Google Scholar
• Chen MW, Cheng TJ, Huang Y et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl Acad. Sci. USA105(36), 13538–13543 (2008).
   PubMed Web of Science ®Google Scholar
• Rao S, Kong WP, Wei CJ et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS ONE3(6), e2432 (2008).
   PubMed Web of Science ®Google Scholar
• Rao SS, Kong WP, Wei CJ et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE5(3), e9812 (2010).
   PubMed Web of Science ®Google Scholar
• Shen S, Mahadevappa G, Oh HL et al. Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J. Med. Virol.80(11), 1972–1983 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai C, Caillet C, Hu H et al. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine27(48), 6777–6790 (2009).
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science329(5995), 1060–1064 (2010).
   PubMed Web of Science ®Google Scholar
• Wei CJ, Xu L, Kong WP et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol.82(13), 6200–6208 (2008).
   PubMedGoogle Scholar
• Yang ZY, Wei CJ, Kong WP et al. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science317(5839), 825–828 (2007).
   PubMed Web of Science ®Google Scholar
• Oh HL, Akerstrom S, Shen S et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J. Virol.84(16), 8275–8286 (2010).
   PubMed Web of Science ®Google Scholar
• Fooks AR, Johnson N, Freuling CM et al. Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century. PLoS Negl. Trop. Dis.3(9), e530 (2009).
   PubMed Web of Science ®Google Scholar
• Wright E, Hayman DT, Vaughan A et al. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology408(2), 183–189 (2010).
   PubMedGoogle Scholar
• Wright E, McNabb S, Goddard T et al. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine27(51), 7178–7186 (2009).
   PubMedGoogle Scholar
• Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol.89(Pt 9), 2204–2213 (2008).
   PubMed Web of Science ®Google Scholar
• Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol.74(10), 4933–4937 (2000).
   PubMed Web of Science ®Google Scholar
• Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol.72(4), 3155–3160 (1998).
   PubMed Web of Science ®Google Scholar
• Ogino M, Ebihara H, Lee BH et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab. Immunol.10(1), 154–160 (2003).
   PubMedGoogle Scholar
• Tamin A, Harcourt BH, Lo MK et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods160(1–2), 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• Fukushi S, Mizutani T, Saijo M et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol.78(12), 1509–1512 (2006).
   PubMed Web of Science ®Google Scholar
• Temperton NJ, Chan PK, Simmons G et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis.11(3), 411–416 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia JM, Lagarde N, Ma ES, de Jong MD, Peiris JS. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J. Clin. Virol.47(1), 29–33 (2010).
   PubMedGoogle Scholar
• Kong WP, Hood C, Yang ZY et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl Acad. Sci. USA103(43), 15987–15991 (2006).
   PubMed Web of Science ®Google Scholar
• Capecchi B, Fasolo A, Albertini I et al. Use of pseudotyped particles expressing Influenza A/Vietnam/1194/2004 hemagglutinin in neutralization assays. In: Options for the Control of Influenza VI. Katz JM (Ed.). International Medical Press, London, UK, 303–305 (2008).
   Google Scholar
• Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK SIAT-1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol.46(7), 2189–2194 (2008).
   PubMed Web of Science ®Google Scholar
• Buchy P, Vong S, Chu S et al. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS ONE5(5), e10864 (2010).
   PubMed Web of Science ®Google Scholar
• Cavailler P, Chu S, Ly S et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J. Clin. Virol.48(2), 123–126 (2010).
   PubMedGoogle Scholar
• Inoue E, Wang X, Osawa Y, Okazaki K. Full genomic amplification and subtyping of influenza A virus using a single set of universal primers. Microbiol. Immunol.54(3), 129–134 (2010).
   PubMed Web of Science ®Google Scholar
• Stech J, Stech O, Herwig A et al. Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification. Nucleic Acids Res.36(21), e139 (2008).
   PubMed Web of Science ®Google Scholar